Derek A. Wainwright, Ph.D.

Very impactful study from the Wainwright Lab at Loyola alongside the Schiltz lab at Northwestern. A new and highly potent IDO1 PROTAC! pubs.acs.org/doi/full/10....
@dwainwright-phd.bsky.social

This new work provides the validation of a new and highly potent drug aimed improving immunotherapeutic efficacy against cancer.

Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC) Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and nonenzymatic functions. Drugs targeting IDO1 enzyme activit...

Happy to share my latest work developing IDO1 degraders. This is the result of a fantastic collaboration with @dwainwright-phd.bsky.social and his group. The medicinal chemistry was led by an amazing postdoctoral fellow Dr. Paige Monsen (now at Foghorn Therapeutics).

pubs.acs.org/doi/10.1021/...